Gainers
- Hoth Therapeutics HOTH shares moved upwards by 6.08% to $0.86 during Wednesday's after-market session. The company's market cap stands at $20.6 million.
- Aileron Therapeutics ALRN shares increased by 5.87% to $0.6. The market value of their outstanding shares is at $54.3 million.
- InspireMD NSPR shares rose 5.6% to $3.77. The company's market cap stands at $30.4 million.
- Tyme Technologies TYME stock moved upwards by 5.05% to $0.7. The company's market cap stands at $120.5 million.
- Trinity Biotech TRIB stock moved upwards by 4.99% to $1.89. The market value of their outstanding shares is at $39.5 million.
- Calithera Biosciences CALA shares moved upwards by 4.57% to $0.8. The company's market cap stands at $59.9 million.
Losers
- 180 Life Sciences ATNF shares decreased by 9.71% to $4.56 during Wednesday's after-market session. Trading volume for this security closed at 81.7K, accounting for 8.97% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $155.1 million.
- Roivant Sciences ROIV stock fell 5.29% to $8.42. The market value of their outstanding shares is at $5.7 billion.
- Veeva Systems VEEV shares fell 4.76% to $259.08. Veeva Systems's trading volume hit 103.4K shares by close, accounting for 14.29% of its average volume over the last 100 days. The market value of their outstanding shares is at $39.7 billion. The company's, Q3 earnings came out today.
- NRX Pharmaceuticals NRXP shares declined by 4.38% to $5.68. The company's market cap stands at $334.0 million.
- Biofrontera BFRI stock decreased by 4.16% to $4.15. The company's market cap stands at $48.1 million. As per the news, the Q3 earnings report came out yesterday.
- Cumberland CPIX shares fell 4.15% to $3.93. Trading volume for this security closed at 122.3K, accounting for 3.48% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $58.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in